glaxosmithkline consumer healthcare (uk) (no.1) limited
glaxosmithkline consumer healthcare (uk) (no.1) limited Company Information
Company Number
00753340
Next Accounts
Sep 2025
Shareholders
haleon uk enterprises limited
Group Structure
View All
Industry
Non-trading company
Registered Address
building 5, first floor, the heights, weybridge, surrey, KT13 0NY
Website
https://www.novartis.co.ukglaxosmithkline consumer healthcare (uk) (no.1) limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED at £0 based on a Turnover of £0 and 0.54x industry multiple (adjusted for size and gross margin).
glaxosmithkline consumer healthcare (uk) (no.1) limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED at £97.5k based on an EBITDA of £23k and a 4.24x industry multiple (adjusted for size and gross margin).
glaxosmithkline consumer healthcare (uk) (no.1) limited Estimated Valuation
Pomanda estimates the enterprise value of GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED at £13.6m based on Net Assets of £10.4m and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited Overview
Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited is a live company located in weybridge, KT13 0NY with a Companies House number of 00753340. It operates in the non-trading company sector, SIC Code 74990. Founded in March 1963, it's largest shareholder is haleon uk enterprises limited with a 100% stake. Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited Health Check
Pomanda's financial health check has awarded Glaxosmithkline Consumer Healthcare (Uk) (No.1) Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
- Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1.4%, this is a lower level of debt than the average (47.9%)
- - Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited
- - Industry AVG
GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED financials
Glaxosmithkline Consumer Healthcare (Uk) (No.1) Limited's latest turnover from December 2023 is 0 and the company has net assets of £10.4 million. According to their latest financial statements, we estimate that Glaxosmithkline Consumer Healthcare (Uk) (No.1) Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 25,145,000 | 73,397,000 | 74,364,000 | 68,596,000 | 64,332,000 | 62,593,000 | 63,459,000 | 61,811,000 | |||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 21,546,000 | 45,660,000 | 44,348,000 | 41,187,000 | 40,473,000 | 37,187,000 | 37,985,000 | 37,144,000 | |||||||
| Gross Profit | 3,599,000 | 27,737,000 | 30,016,000 | 27,409,000 | 23,859,000 | 25,406,000 | 25,474,000 | 24,667,000 | |||||||
| Admin Expenses | -23,000 | 9,000 | -11,000 | 34,702,000 | 25,528,000 | 30,817,000 | 25,307,000 | 24,233,000 | 23,788,000 | 23,282,000 | 21,468,000 | ||||
| Operating Profit | 23,000 | -9,000 | -20,000 | -14,000 | -13,000 | -65,000 | 11,000 | -31,103,000 | 2,209,000 | -801,000 | 2,102,000 | -374,000 | 1,618,000 | 2,192,000 | 3,199,000 |
| Interest Payable | 1,000 | 14,000 | 38,000 | 33,000 | 48,000 | 33,000 | 144,000 | 154,000 | 139,000 | 100,000 | |||||
| Interest Receivable | 454,000 | 128,000 | 13,000 | 57,000 | 38,000 | 5,000 | 1,000 | 8,000 | 7,000 | ||||||
| Pre-Tax Profit | 477,000 | 119,000 | -20,000 | -1,000 | 43,000 | -27,000 | -3,000 | -30,052,000 | 2,176,000 | -849,000 | 2,069,000 | -517,000 | 1,464,000 | 2,061,000 | 3,106,000 |
| Tax | -105,000 | -23,000 | 4,000 | -8,000 | 5,000 | 5,825,000 | -871,000 | -620,000 | 254,000 | -617,000 | 198,000 | -391,000 | -1,551,000 | -873,000 | |
| Profit After Tax | 372,000 | 96,000 | -16,000 | -1,000 | 35,000 | -22,000 | 5,822,000 | -30,923,000 | 1,556,000 | -595,000 | 1,452,000 | -319,000 | 1,073,000 | 510,000 | 2,233,000 |
| Dividends Paid | |||||||||||||||
| Retained Profit | 372,000 | 96,000 | -16,000 | -1,000 | 35,000 | -22,000 | 5,822,000 | -30,923,000 | 1,556,000 | -595,000 | 1,452,000 | -319,000 | 1,073,000 | 510,000 | 2,233,000 |
| Employee Costs | 946,000 | 6,049,000 | 7,211,000 | 6,168,000 | 5,669,000 | 6,382,000 | 5,400,000 | 5,974,000 | |||||||
| Number Of Employees | 7 | 50 | 73 | 75 | 73 | 69 | 73 | 79 | |||||||
| EBITDA* | 23,000 | -9,000 | -20,000 | -14,000 | -13,000 | -65,000 | 11,000 | -31,103,000 | 2,209,000 | -801,000 | 2,102,000 | -374,000 | 1,625,000 | 2,210,000 | 3,241,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 4,000 | 818,000 | 1,641,000 | ||||||||||||
| Intangible Assets | 502,000 | ||||||||||||||
| Investments & Other | 1,210,000 | ||||||||||||||
| Debtors (Due After 1 year) | 950,000 | ||||||||||||||
| Total Fixed Assets | 502,000 | 950,000 | 1,214,000 | 818,000 | 1,641,000 | ||||||||||
| Stock & work in progress | 8,760,000 | 8,318,000 | 8,877,000 | 6,669,000 | 7,096,000 | 9,569,000 | 9,050,000 | ||||||||
| Trade Debtors | 13,815,000 | 13,813,000 | 10,993,000 | 11,274,000 | 10,346,000 | 10,293,000 | 11,686,000 | ||||||||
| Group Debtors | 10,531,000 | 10,073,000 | 9,948,000 | 9,949,000 | 9,950,000 | 9,911,000 | 9,893,000 | 6,500,000 | 1,417,000 | 397,000 | 198,000 | 457,000 | 341,000 | 460,000 | 699,000 |
| Misc Debtors | 4,000 | 2,000 | 6,000 | 8,000 | 48,000 | 1,280,000 | 620,000 | 717,000 | 1,153,000 | 868,000 | 610,000 | 440,000 | 930,000 | ||
| Cash | 10,083,000 | 741,000 | 3,927,000 | 2,648,000 | 2,923,000 | 3,703,000 | 5,111,000 | ||||||||
| misc current assets | 1,518,000 | 1,717,000 | 1,893,000 | 233,000 | 729,000 | ||||||||||
| total current assets | 10,531,000 | 10,073,000 | 9,952,000 | 9,951,000 | 9,956,000 | 9,919,000 | 9,941,000 | 7,780,000 | 36,213,000 | 25,703,000 | 27,041,000 | 22,149,000 | 22,045,000 | 24,465,000 | 27,476,000 |
| total assets | 10,531,000 | 10,073,000 | 9,952,000 | 9,951,000 | 9,956,000 | 9,919,000 | 9,941,000 | 7,780,000 | 36,213,000 | 25,703,000 | 27,543,000 | 23,099,000 | 23,259,000 | 25,283,000 | 29,117,000 |
| Bank overdraft | 5,213,000 | 4,570,000 | 3,900,000 | ||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 5,930,000 | 3,614,000 | 3,704,000 | 4,687,000 | 3,825,000 | 3,503,000 | 4,795,000 | ||||||||
| Group/Directors Accounts | 18,000 | 41,000 | 35,000 | 18,000 | 14,000 | 20,000 | 20,000 | 3,681,000 | 14,143,000 | 7,365,000 | 6,446,000 | 5,032,000 | 7,449,000 | 5,000,000 | 1,000,000 |
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 128,000 | 19,000 | 8,000 | 3,827,000 | 5,398,000 | 6,831,000 | 5,387,000 | 7,155,000 | 13,040,000 | 19,397,000 | |||||
| total current liabilities | 146,000 | 60,000 | 35,000 | 18,000 | 22,000 | 20,000 | 20,000 | 3,681,000 | 23,900,000 | 21,590,000 | 21,551,000 | 19,006,000 | 18,429,000 | 21,543,000 | 25,192,000 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 3,208,000 | 9,192,000 | |||||||||||||
| total long term liabilities | 8,334,000 | 6,737,000 | 8,462,000 | 4,127,000 | 4,836,000 | 1,604,000 | 4,596,000 | ||||||||
| total liabilities | 146,000 | 60,000 | 35,000 | 18,000 | 22,000 | 20,000 | 20,000 | 3,681,000 | 32,234,000 | 28,327,000 | 30,013,000 | 23,133,000 | 23,265,000 | 23,147,000 | 29,788,000 |
| net assets | 10,385,000 | 10,013,000 | 9,917,000 | 9,933,000 | 9,934,000 | 9,899,000 | 9,921,000 | 4,099,000 | 3,979,000 | -2,624,000 | -2,470,000 | -34,000 | -6,000 | 2,136,000 | -671,000 |
| total shareholders funds | 10,385,000 | 10,013,000 | 9,917,000 | 9,933,000 | 9,934,000 | 9,899,000 | 9,921,000 | 4,099,000 | 3,979,000 | -2,624,000 | -2,470,000 | -34,000 | -6,000 | 2,136,000 | -671,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 23,000 | -9,000 | -20,000 | -14,000 | -13,000 | -65,000 | 11,000 | -31,103,000 | 2,209,000 | -801,000 | 2,102,000 | -374,000 | 1,618,000 | 2,192,000 | 3,199,000 |
| Depreciation | 7,000 | 18,000 | 42,000 | ||||||||||||
| Amortisation | |||||||||||||||
| Tax | -105,000 | -23,000 | 4,000 | -8,000 | 5,000 | 5,825,000 | -871,000 | -620,000 | 254,000 | -617,000 | 198,000 | -391,000 | -1,551,000 | -873,000 | |
| Stock | -8,760,000 | 442,000 | -559,000 | 2,208,000 | -427,000 | -2,473,000 | 519,000 | 9,050,000 | |||||||
| Debtors | 458,000 | 121,000 | 1,000 | -5,000 | 37,000 | -22,000 | 2,161,000 | -8,072,000 | 925,000 | 2,583,000 | -1,205,000 | 2,252,000 | 104,000 | -2,122,000 | 13,315,000 |
| Creditors | -5,930,000 | 2,316,000 | -90,000 | -983,000 | 862,000 | 322,000 | -1,292,000 | 4,795,000 | |||||||
| Accruals and Deferred Income | 109,000 | 19,000 | -8,000 | 8,000 | -3,827,000 | -1,571,000 | -1,433,000 | 1,444,000 | -1,768,000 | -5,885,000 | -6,357,000 | 19,397,000 | |||
| Deferred Taxes & Provisions | -3,208,000 | -5,984,000 | 9,192,000 | ||||||||||||
| Cash flow from operations | -431,000 | -134,000 | -17,000 | -17,000 | -50,000 | -38,000 | 3,675,000 | -24,899,000 | 967,000 | -4,094,000 | 943,000 | -2,907,000 | -5,168,000 | -11,371,000 | 13,387,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | -1,210,000 | 1,210,000 | |||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -23,000 | 6,000 | 17,000 | 4,000 | -6,000 | -3,661,000 | -10,462,000 | 6,778,000 | 919,000 | 1,414,000 | -2,417,000 | 2,449,000 | 4,000,000 | 1,000,000 | |
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 454,000 | 128,000 | 13,000 | 56,000 | 38,000 | -14,000 | -33,000 | -33,000 | -48,000 | -33,000 | -143,000 | -154,000 | -131,000 | -93,000 | |
| cash flow from financing | 431,000 | 134,000 | 17,000 | 17,000 | 50,000 | 38,000 | -3,675,000 | 20,548,000 | 11,792,000 | 1,312,000 | -2,507,000 | -2,269,000 | -920,000 | 6,166,000 | -1,997,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -10,083,000 | 9,342,000 | -3,186,000 | 1,279,000 | -275,000 | -780,000 | -1,408,000 | 5,111,000 | |||||||
| overdraft | -5,213,000 | 643,000 | 670,000 | 3,900,000 | |||||||||||
| change in cash | -10,083,000 | 14,555,000 | -3,829,000 | 609,000 | -4,175,000 | -780,000 | -1,408,000 | 5,111,000 |
glaxosmithkline consumer healthcare (uk) (no.1) limited Credit Report and Business Information
Glaxosmithkline Consumer Healthcare (uk) (no.1) Limited Competitor Analysis
Perform a competitor analysis for glaxosmithkline consumer healthcare (uk) (no.1) limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in KT13 area or any other competitors across 12 key performance metrics.
glaxosmithkline consumer healthcare (uk) (no.1) limited Ownership
GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED group structure
Glaxosmithkline Consumer Healthcare (Uk) (No.1) Limited has no subsidiary companies.
Ultimate parent company
2 parents
GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED
00753340
glaxosmithkline consumer healthcare (uk) (no.1) limited directors
Glaxosmithkline Consumer Healthcare (Uk) (No.1) Limited currently has 4 directors. The longest serving directors include Antrinkos Aristidou (Aug 2019) and Mr Nicholas Cooper (Sep 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Antrinkos Aristidou | England | 56 years | Aug 2019 | - | Director |
| Mr Nicholas Cooper | England | 52 years | Sep 2019 | - | Director |
| Mr David Cottam | England | 62 years | Jul 2020 | - | Director |
| Mrs Carole Phillips | England | 45 years | Mar 2022 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
23k
-356%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
10.4m
+0.04%
total assets
10.5m
+0.05%
cash
0
0%
net assets
Total assets minus all liabilities
glaxosmithkline consumer healthcare (uk) (no.1) limited company details
company number
00753340
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
March 1963
age
62
incorporated
UK
ultimate parent company
accounts
Audit Exemption Subsidiary
last accounts submitted
December 2023
previous names
novartis consumer health uk limited (June 2018)
zyma (united kingdom) limited (January 1997)
accountant
-
auditor
-
address
building 5, first floor, the heights, weybridge, surrey, KT13 0NY
Bank
HSBC BANK PLC
Legal Advisor
-
glaxosmithkline consumer healthcare (uk) (no.1) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to glaxosmithkline consumer healthcare (uk) (no.1) limited.
glaxosmithkline consumer healthcare (uk) (no.1) limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED. This can take several minutes, an email will notify you when this has completed.
glaxosmithkline consumer healthcare (uk) (no.1) limited Companies House Filings - See Documents
| date | description | view/download |
|---|
